<DOC>
	<DOC>NCT02509234</DOC>
	<brief_summary>The purpose of the study is to evaluate patients with refractory childhood sarcomas, who have been treated with a combination therapy of trabectedin and irinotecan (within compassionate use), to determine, if this is a promising treatment option with acceptable toxicity and if the results warrant a prospective study.</brief_summary>
	<brief_title>Trabectedin and Irinotecan for Refractory Pediatric Sarcomas</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma, Ewing</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Adolescents and young adults (age10 40 yoa) with refractory sarcoma, for which there are presently no further treatment options in EUROEwing/ EURAMOS/CWS (i.e. â‰¥ second relapse in ES, resistance to surgery in osteosarcoma, relapsed rhabdomyosarcoma) and have been treated with a combined chemotherapy of trabectedin and irinotecan (described in intervention) existing matched control in existing study databases have started of treatment within three months of last progress Key Patients newly diagnosed or in first relapse.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>pediatric sarcomas</keyword>
	<keyword>Ewing sarcoma</keyword>
	<keyword>rhabdomyosarcoma</keyword>
	<keyword>soft tissue sarcoma</keyword>
</DOC>